To determine whether FADS1 and FADS2 contribute to ven + aza resistance in relapsed AML, we observed viability in de novo and relapsed ROS-Low primary AML cells using pharmacological FADS1 and FADS2 inhibitors. The gene discussed is FADS2; the disease is acute myeloid leukemia.